(redirected from ATTR amyloidosis)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to ATTR amyloidosis: Hereditary amyloidosis, familial amyloidosis


Any of a group of diseases or conditions characterized by the formation and deposition of amyloid in various organs and tissues of the body.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


(Pathology) pathol the deposition of amyloid in various tissues of the body, as occurs in certain chronic infections
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.amyloidosis - a disorder characterized by deposit of amyloid in organs or tissues; often secondary to chronic rheumatoid arthritis or tuberculosis or multiple myeloma
illness, sickness, unwellness, malady - impairment of normal physiological function affecting part or all of an organism
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.


n. amiloidosis, acumulación de amiloide en los tejidos.
English-Spanish Medical Dictionary © Farlex 2012


n amiloidosis f
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
Alnylam Pharmaceuticals shared new findings at the Second European Meeting of ATTR Amyloidosis, or EU-ATTR, for Doctors and Patients, being held September 2-3, in Berlin, Germany.
Coffee Symposium for Doctors by Akcea - Multidisciplinary care for Hereditary ATTR Amyloidosis: A 360 Degree Perspective
"Our alliance with Alnylam has successfully brought one important medicine to patients with ATTR amyloidosis and it also has spawned a molecule that is in pivotal clinical trials for people with hemophilia," said John Reed, global head of R&D at Sanofi.
Onpattro has been developed to meet a significant unmet need for patients with hereditary ATTR amyloidosis, a devastating, chronic and often fatal disease.
Thus, myocardial scintigraphy can diagnose cardiac ATTR amyloidosis without histological confirmation as long as there is no plasma cell dyscrasia [15, 17].
The most common forms of amyloidosis include systemic AL amyloidosis (formerly primary amyloidosis), systemic AA amyloidosis (formerly secondary amyloidosis), systemic wild-type ATTR amyloidosis (formerly age-related or senile systemic amyloidosis), systemic hereditary ATTR amyloidosis (formerly familial amyloid polyneuropathy), and localized AL amyloidosis (Table 1).
ATTR amyloidosis originates from a number of DNA mutations (autosomal dominant inheritance, more than 100 mutations) of the transthyretin (TTR) protein which is synthesized in the liver.
Burden had ATTR amyloidosis, a disease that causes the body's immune system to produce abnormal forms of antibodies, and had been treated at New York Presbyterian Hospital.
Ionis and Akcea plan to present data from the Phase 1/2 study of AKCEA-TTR-LRxin healthy volunteers in September 2019 at the European ATTR Amyloidosis meeting and at the Heart Failure Society of America.
Alnylam Pharmaceuticals announced new results from the Global Open-Label Extension study of ONPATTRO, an RNAi therapeutic for the treatment of the polyneuropathy of hereditary ATTR amyloidosis. In addition, the Company reported on new analyses from the APOLLO Phase 3 study of patisiran and results of an indirect treatment comparison of patisiran and inotersen.